Zyrtec 24 Hour Allergy Relief Tablets

Zyrtec (cetirizine hydrochloride) is a leading antihistamine brand originally developed by the Belgian pharmaceutical company UCB. It was first launched in the United States in the mid-1990s through a co-marketing agreement between UCB and Pfizer. Over the decades, the brand's ownership shifted through significant corporate restructurings. It eventually became part of the Johnson & Johnson Consumer Health division.

In 2023, Johnson & Johnson spun off its consumer health business into a standalone public company named Kenvue. In a major industry consolidation announced in late 2025, Kimberly-Clark Corporation agreed to acquire Kenvue for approximately $48.7 billion. This transaction, expected to conclude in the second half of 2026, places Zyrtec under the ultimate ownership of Kimberly-Clark, a global leader in personal care products.

While the specific package in the image is typically distributed in the U.S. by Kenvue's subsidiaries (such as McNeil Consumer Healthcare), manufacturing for Zyrtec occurs in multiple locations worldwide, including facilities in the United States and specialized pharmaceutical plants in Europe and Asia, to satisfy its extensive global demand.